Biogen (NASDAQ:BIIB) Shares Gap Down – Here’s Why

Biogen Inc. (NASDAQ:BIIB)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $187.57, but opened at $179.46. Biogen shares last traded at $179.6680, with a volume of 410,474 shares changing hands.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen agreed to acquire Apellis for about $5.6 billion in cash, bringing two commercial immunology/rare‑disease drugs (SYFOVRE®, EMPAVELI®) and a nephrology launch capability — expected to boost near‑term revenue and diversify Biogen beyond MS. Biogen to buy Apellis Pharmaceuticals for $5.6 billion (Reuters)
• Positive Sentiment: Analysts reacted with higher price targets and constructive coverage: Oppenheimer raised its PT to $275 (outperform) and Canaccord to $245 (buy), lifting sentiment that the deal and other pipeline wins improve Biogen’s growth profile. Oppenheimer raises Biogen price target (MarketScreener)
• Positive Sentiment: FDA approval of a higher‑dose SPINRAZA regimen supports Biogen’s rare‑disease revenues and reduces competitive risk in SMA, adding another near‑term commercial tailwind alongside Apellis assets. Biogen secures FDA nod for higher‑dose SPINRAZA (Zacks)
• Neutral Sentiment: Biogen management says combined cash flow from Biogen + Apellis should improve leverage ratios and free capacity for further deals — management framing the purchase as strategic rather than one‑off. Biogen CFO comments on cash flow and M&A capacity (BioPharmaDive)
• Neutral Sentiment: Apellis shares surged (more than doubled) on the takeover premium; that rally reflects deal certainty for Apellis but only partially signals upside for Biogen beyond the strategic rationale. Apellis hits multi‑year high on Biogen deal (Yahoo Finance)
• Negative Sentiment: An investor law firm has opened an investigation into the adequacy of the Apellis sale price/process, which could signal proxy litigation or shareholder pushback that complicates or delays closing. Investor investigation into Apellis sale process (BusinessWire)
• Negative Sentiment: Some analysts remain cautious (Hold ratings cited), pointing to execution risk on Leqembi/ MS erosion, integration risk and the cash outflow’s near‑term impact — these concerns help explain any initial pressure on Biogen shares after the deal news. Analyst caution/hold ratings despite positives (TipRanks)

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Wolfe Research set a $231.00 price target on shares of Biogen in a research note on Monday, February 9th. Weiss Ratings restated a “hold (c-)” rating on shares of Biogen in a report on Monday, December 29th. Wells Fargo & Company increased their target price on Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Sunday, February 8th. UBS Group initiated coverage on Biogen in a report on Tuesday, January 6th. They issued a “neutral” rating and a $185.00 target price on the stock. Finally, BMO Capital Markets boosted their price target on Biogen from $165.00 to $196.00 and gave the company a “market perform” rating in a research report on Friday, February 6th. Twelve investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Biogen presently has an average rating of “Hold” and a consensus price target of $207.96.

Biogen Trading Up 0.2%

The firm’s 50 day simple moving average is $186.41 and its 200-day simple moving average is $171.07. The company has a market capitalization of $26.97 billion, a PE ratio of 20.86, a P/E/G ratio of 1.46 and a beta of 0.16. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last issued its earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The business had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business’s revenue for the quarter was down 7.2% compared to the same quarter last year. During the same quarter last year, the firm posted $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, equities research analysts anticipate that Biogen Inc. will post 15.83 EPS for the current year.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider directly owned 8,043 shares of the company’s stock, valued at $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.18% of the stock is owned by company insiders.

Institutional Investors Weigh In On Biogen

Institutional investors and hedge funds have recently modified their holdings of the stock. Empowered Funds LLC lifted its position in Biogen by 64.9% during the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after acquiring an additional 2,777 shares in the last quarter. Focus Partners Wealth grew its position in Biogen by 172.2% in the first quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after acquiring an additional 6,436 shares in the last quarter. Sivia Capital Partners LLC purchased a new stake in shares of Biogen during the second quarter valued at approximately $216,000. American Century Companies Inc. raised its stake in shares of Biogen by 34.4% during the second quarter. American Century Companies Inc. now owns 81,253 shares of the biotechnology company’s stock valued at $10,205,000 after purchasing an additional 20,778 shares during the period. Finally, J.W. Cole Advisors Inc. acquired a new position in shares of Biogen during the second quarter worth $253,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.